JP2014201591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014201591A5 JP2014201591A5 JP2014077939A JP2014077939A JP2014201591A5 JP 2014201591 A5 JP2014201591 A5 JP 2014201591A5 JP 2014077939 A JP2014077939 A JP 2014077939A JP 2014077939 A JP2014077939 A JP 2014077939A JP 2014201591 A5 JP2014201591 A5 JP 2014201591A5
- Authority
- JP
- Japan
- Prior art keywords
- exposure
- ionizing radiation
- image processing
- medical image
- genistein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 17
- 230000005865 ionizing radiation Effects 0.000 claims 7
- 238000002059 diagnostic imaging Methods 0.000 claims 4
- 229940045109 genistein Drugs 0.000 claims 4
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 claims 4
- 235000006539 genistein Nutrition 0.000 claims 4
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 2
- 230000000116 mitigating effect Effects 0.000 claims 2
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 claims 1
- 206010007747 Cataract congenital Diseases 0.000 claims 1
- 208000032170 Congenital Abnormalities Diseases 0.000 claims 1
- 208000035967 Long Term Adverse Effects Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000002591 computed tomography Methods 0.000 claims 1
- 230000002939 deleterious effect Effects 0.000 claims 1
- 230000005782 double-strand break Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000009931 harmful effect Effects 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 239000006070 nanosuspension Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/856,909 | 2013-04-04 | ||
| US13/856,909 US9623003B1 (en) | 2013-04-04 | 2013-04-04 | Method of mitigating long and short term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014201591A JP2014201591A (ja) | 2014-10-27 |
| JP2014201591A5 true JP2014201591A5 (enExample) | 2017-05-25 |
Family
ID=50439162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014077939A Pending JP2014201591A (ja) | 2013-04-04 | 2014-04-04 | 医用画像処理電離放射線被曝の長期的および短期的な有害な影響をゲニステインの投与により軽減する方法 |
Country Status (3)
| Country | Link |
|---|---|
| US (3) | US9623003B1 (enExample) |
| EP (1) | EP2786751A1 (enExample) |
| JP (1) | JP2014201591A (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9623003B1 (en) | 2013-04-04 | 2017-04-18 | Humanetics Corporation | Method of mitigating long and short term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein |
| US9623004B2 (en) | 2013-08-02 | 2017-04-18 | Humanetics Corporation | Administration of a therapeutic amount of genistein to mitigate erectile dysfunction resulting from radiation therapy for prostate cancer only throughout a defined administration period commencing shortly before and concluding after radiation therapy |
| US20150126597A1 (en) * | 2013-11-07 | 2015-05-07 | Humanetics Corporation | Genistein cancer treatment regimen maximizing cancer radiation therapy benefits |
| CA3207497A1 (en) * | 2021-01-11 | 2022-07-14 | Humanetics Corporation | Genistein treatment of inflammatory and immunological disorders |
| CN114948869A (zh) * | 2022-05-26 | 2022-08-30 | 中国药科大学 | 一种染料木素纳米混悬液的制备方法及该方法制备的染料木素纳米混悬液 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5523087A (en) | 1995-02-15 | 1996-06-04 | Bio-Virus Research Incorporated | Pharmaceutical compositions for the treatment of diabetic male sexual dysfunction |
| US5824702A (en) | 1996-06-07 | 1998-10-20 | Mount Sinai School Of Medicine Of The City University Of New York | Genistein as a preventive against ultraviolet induced skin photodamage and cancer |
| JP3502374B2 (ja) | 1999-08-27 | 2004-03-02 | チェイル ジェダン コーポレーション | プエラリア・ミリフィカ、ブテア・スペルバおよび／またはムクナ・コレッチ由来の抽出物並びにその抽出方法 |
| ES2288169T3 (es) | 2000-06-14 | 2008-01-01 | The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Isoflavonas contra la mortalidad inducida por radiacion. |
| CA2416796A1 (en) | 2000-06-14 | 2001-12-20 | Alla Shapiro | Radioprotective agents |
| GB0302882D0 (en) | 2003-02-07 | 2003-03-12 | Univ Cardiff | Improvements in or relating to agents for the treatment of cardiovascular dysfunction and weight loss |
| WO2006091187A1 (en) | 2005-02-22 | 2006-08-31 | Landauer Michael R | Isoflavonoids for preventing radiation- and chemotherapy- induced weight loss |
| ES2369928T3 (es) | 2005-06-29 | 2011-12-09 | Dsm Ip Assets B.V. | Nanopartículas de isoflavonas y su utilización. |
| CN102933258A (zh) | 2010-03-01 | 2013-02-13 | 因特奥普医药公司 | 与含氧量低的细胞敏化剂联用的放疗 |
| US8900635B2 (en) | 2010-11-15 | 2014-12-02 | Humanetics Corporation | Nanoparticle isoflavone compositions and methods of making and using the same |
| US9623003B1 (en) | 2013-04-04 | 2017-04-18 | Humanetics Corporation | Method of mitigating long and short term detrimental effects of exposure to medical imaging ionizing radiation by administration of genistein |
-
2013
- 2013-04-04 US US13/856,909 patent/US9623003B1/en active Active
-
2014
- 2014-03-26 EP EP20140161725 patent/EP2786751A1/en not_active Withdrawn
- 2014-04-04 JP JP2014077939A patent/JP2014201591A/ja active Pending
-
2017
- 2017-03-06 US US15/450,628 patent/US9993455B2/en active Active
-
2018
- 2018-05-11 US US15/977,023 patent/US10220018B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202107358B (en) | Method for treating alzheimer's disease | |
| WO2017116530A3 (en) | Radioabsorbent assemblies | |
| WO2018022668A3 (en) | NEUROMODULATORY COMPOSITIONS AND ASSOCIATED METHODS OF TREATING CANCER | |
| MX2021004828A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
| MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
| MX377576B (es) | Formulaciones de pridopidina de liberación modificada. | |
| MX395482B (es) | Compuestos antiproliferativos y metodos de uso de los mismos | |
| JP2016519107A5 (enExample) | ||
| JP2014201591A5 (enExample) | ||
| MY199027A (en) | Method for treating or preventing ophthalmological conditions | |
| WO2015183346A3 (en) | Imaging and treatment of pathophysiologic conditions by cerenkov radiation | |
| MX395637B (es) | Composiciones de alergenos alimentarios. | |
| MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
| HK1217092A1 (zh) | 治疗性化合物及其用途 | |
| EP3442542A4 (en) | NANOPARTICLE, DOSAGE FORM WITH CONTROLLED RELEASE, AND METHOD FOR RELEASING AN IMMUNOTHERAPEUTIC | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112017005313A2 (pt) | formação de imagem e terapia para inflamação e infecção direcionadas por hsp90 | |
| JP2019532047A5 (enExample) | ||
| ZA201704327B (en) | Methods and compositions for treating brain diseases | |
| HK1251488A1 (zh) | 作为放射致敏剂以及mri和/或x光造影剂的结合纳米粒子的抗核仁素剂 | |
| MX2015012315A (es) | Uso de levocetirizina y montelukast en el tratamiento de lesion traumatica. | |
| CY1119532T1 (el) | (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη | |
| NZ754328A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
| EP4410295A3 (en) | Use of vibegron to treat overactive bladder | |
| BR112016029437A2 (pt) | métodos para tratamento e prevenção de doenças de instabilidade vascular |